Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | FBP1 | P09467 | 2/20 | 0.44 |
| ▸ | PTGES | O14684 | 4/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3101725 | 0.82 | HTR3E (0.55) | HTR6PTGESPTGS2 | |
| SCHEMBL3917839 | 0.80 | HTR6 (0.73) | HTR6 | |
| SCHEMBL3918109 | 0.79 | HTR6 (1.00) | HTR6 | |
| SCHEMBL4079946 | 0.79 | HTR6 (1.00) | HTR6USP2 | |
| SCHEMBL4082403 | 0.79 | HTR6 (0.71) | HTR6USP2 | |
| Hydrochloric Acid SCHEMBL4084900 | 0.78 | HTR6 (0.98) | HTR6 | |
| SCHEMBL3082150 | 0.77 | PTGES (0.53) | HTR6PTGESPTGS2 | |
| SCHEMBL14064153 | 0.77 | HTR6 (0.62) | HTR6 | |
| Hydrochloric Acid SCHEMBL4057635 | 0.76 | HTR6 (0.61) | HTR6 | |
| SCHEMBL3104207 | 0.74 | SOS1 (0.61) | HTR6PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501421-B2 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-03-10 | — | — | US | claimed |
| EP-2024348-A2 | BENZOXAZOLE AND BENZOTHIAZOLE DERIVATIVES AS 5-HYDROXYTRYTAMINE-6 LIGANDS | Wyeth (US) | 2009-02-18 | — | — | EP | claimed |
| WO-2007142904-A2 | BENZOXAZOLE AND BENZOTHIAZOLE DERIVATIVES AS 5-HYDROXYTRYTAMINE-6 LIGANDS | WYETH (US) | 2007-12-13 | — | — | WO | claimed |
| US-20070281945-A1 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-12-06 | — | — | US | claimed |
| US-7501421-B2 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-03-10 | — | — | US | disclosed |
| US-20070281945-A1 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281945-A1 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | HTR6 1/4885USP2 3849/4885FBP1 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.